Demographic and Clinical Factors Associated With SARS-CoV-2 Spike 1 Antibody Response Among Vaccinated US Adults: the C4R Study.

Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
19 Feb 2024
Historique:
received: 05 05 2023
accepted: 24 01 2024
medline: 20 2 2024
pubmed: 20 2 2024
entrez: 19 2 2024
Statut: epublish

Résumé

This study investigates correlates of anti-S1 antibody response following COVID-19 vaccination in a U.S. population-based meta-cohort of adults participating in longstanding NIH-funded cohort studies. Anti-S1 antibodies were measured from dried blood spots collected between February 2021-August 2022 using Luminex-based microsphere immunoassays. Of 6245 participants, mean age was 73 years (range, 21-100), 58% were female, and 76% were non-Hispanic White. Nearly 52% of participants received the BNT162b2 vaccine and 48% received the mRNA-1273 vaccine. Lower anti-S1 antibody levels are associated with age of 65 years or older, male sex, higher body mass index, smoking, diabetes, COPD and receipt of BNT16b2 vaccine (vs mRNA-1273). Participants with a prior infection, particularly those with a history of hospitalized illness, have higher anti-S1 antibody levels. These results suggest that adults with certain socio-demographic and clinical characteristics may have less robust antibody responses to COVID-19 vaccination and could be prioritized for more frequent re-vaccination.

Identifiants

DOI: 10.1038/s41467-024-45468-9 PMID: 38374032
pubmed: 38374032
doi: 10.1038/s41467-024-45468-9
pii: 10.1038/s41467-024-45468-9
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1492

Informations de copyright

© 2024. The Author(s).

Références

Shiels, M. S., Haque, A. T., Berrington de Gonzalez, A. & Freedman, N. D. Leading causes of death in the US during the COVID-19 pandemic, March 2020 to October 2021. JAMA Intern. Med. 182, 883–886 (2022).
doi: 10.1001/jamainternmed.2022.2476 pubmed: 35788262 pmcid: 9257676
Polack, F. P. et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med. 383, 2603–2615 (2020).
doi: 10.1056/NEJMoa2034577 pubmed: 33301246
Baden, L. R. et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 384, 403–416 (2021).
doi: 10.1056/NEJMoa2035389 pubmed: 33378609
Barouch, D. H. Covid-19 vaccines - immunity, variants, boosters. N. Engl. J. Med. 387, 1011–1020 (2022).
doi: 10.1056/NEJMra2206573 pubmed: 36044620
Perez-Alos, L. et al. Modeling of waning immunity after SARS-CoV-2 vaccination and influencing factors. Nat. Commun. 13, 1614 (2022).
doi: 10.1038/s41467-022-29225-4 pubmed: 35347129 pmcid: 8960902
Levin, E. G. et al. Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months. N. Engl. J. Med., https://doi.org/10.1056/NEJMoa2114583 (2021).
Shrotri, M. et al. Spike-antibody waning after second dose of BNT162b2 or ChAdOx1. Lancet 398, 385–387 (2021).
doi: 10.1016/S0140-6736(21)01642-1 pubmed: 34274038 pmcid: 8285117
Khoury, D. S. et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat. Med. 27, 1205–1211 (2021).
doi: 10.1038/s41591-021-01377-8 pubmed: 34002089
Wei, J. et al. Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccines. Nat. Med. 28, 1072–1082 (2022).
doi: 10.1038/s41591-022-01721-6 pubmed: 35165453 pmcid: 9117148
Earle, K. A. et al. Evidence for antibody as a protective correlate for COVID-19 vaccines. Vaccine 39, 4423–4428 (2021).
doi: 10.1016/j.vaccine.2021.05.063 pubmed: 34210573 pmcid: 8142841
Van Praet, J. T., Vandecasteele, S., De Roo, A., De Vriese, A. S. & Reynders, M. Humoral and cellular immunogenicity of the BNT162b2 Messenger RNA Coronavirus disease 2019 vaccine in nursing home residents. Clin Infect Dis 73, 2145–2147 (2021).
doi: 10.1093/cid/ciab300 pubmed: 33825869
Smoot, K. et al. Persistence and protective potential of SARS-CoV-2 antibody levels After COVID-19 vaccination in a West Virginia Nursing Home Cohort. JAMA Netw Open 5, e2231334 (2022).
doi: 10.1001/jamanetworkopen.2022.31334 pubmed: 36098966 pmcid: 9471977
Steensels, D., Pierlet, N., Penders, J., Mesotten, D. & Heylen, L. Comparison of SARS-CoV-2 antibody response following vaccination with BNT162b2 and mRNA-1273. JAMA, https://doi.org/10.1001/jama.2021.15125 (2021).
Ward, H. et al. Population antibody responses following COVID-19 vaccination in 212,102 individuals. Nat. Commun. 13, 907 (2022).
doi: 10.1038/s41467-022-28527-x pubmed: 35173150 pmcid: 8850615
Shrotri, M. et al. Spike-antibody responses to COVID-19 vaccination by demographic and clinical factors in a prospective community cohort study. Nat. Commun. 13, 5780 (2022).
doi: 10.1038/s41467-022-33550-z pubmed: 36184633 pmcid: 9526787
Oelsner, E. C. et al. Collaborative cohort of cohorts for COVID-19 Research (C4R) Study: Study design. Am. J. Epidemiol. 191, 1153–1173 (2022).
doi: 10.1093/aje/kwac032 pubmed: 35279711
Wei, J. et al. Antibody responses to SARS-CoV-2 vaccines in 45,965 adults from the general population of the United Kingdom. Nat. Microbiol. 6, 1140–1149 (2021).
doi: 10.1038/s41564-021-00947-3 pubmed: 34290390 pmcid: 8294260
Wang, Y. et al. Kinetics of viral load and antibody response in relation to COVID-19 severity. J. Clin. Invest. 130, 5235–5244 (2020).
doi: 10.1172/JCI138759 pubmed: 32634129 pmcid: 7524490
Robbiani, D. F. et al. Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Nature 584, 437–442 (2020).
doi: 10.1038/s41586-020-2456-9 pubmed: 32555388 pmcid: 7442695
Roltgen, K. et al. Defining the features and duration of antibody responses to SARS-CoV-2 infection associated with disease severity and outcome. Sci. Immunol. 5, https://doi.org/10.1126/sciimmunol.abe0240 (2020).
Guan, W. J. et al. Clinical characteristics of Coronavirus disease 2019 in China. N. Engl. J. Med. 382, 1708–1720 (2020).
doi: 10.1056/NEJMoa2002032 pubmed: 32109013
Team, C. C.-R. Preliminary estimates of the prevalence of selected underlying health conditions among patients with Coronavirus Disease 2019 - United States, February 12-March 28, 2020. MMWR Morb. Mortal Wkly Rep. 69, 382–386 (2020).
doi: 10.15585/mmwr.mm6913e2
Cummings, M. J. et al. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. Lancet 395, 1763–1770 (2020).
doi: 10.1016/S0140-6736(20)31189-2 pubmed: 32442528 pmcid: 7237188
Schultze, J. L. & Aschenbrenner, A. C. COVID-19 and the human innate immune system. Cell 184, 1671–1692 (2021).
doi: 10.1016/j.cell.2021.02.029 pubmed: 33743212 pmcid: 7885626
Pajon, R. et al. SARS-CoV-2 Omicron variant neutralization after mRNA-1273 booster vaccination. N. Engl. J. Med. 386, 1088–1091 (2022).
doi: 10.1056/NEJMc2119912 pubmed: 35081298
Eliakim-Raz, N. et al. Antibody titers before and after a third dose of the SARS-CoV-2 BNT162b2 vaccine in adults aged >/=60 Years. JAMA 326, 2203–2204 (2021).
doi: 10.1001/jama.2021.19885 pubmed: 34739043 pmcid: 8652594
Boyarsky, B. J. et al. Antibody response to 2-dose SARS-CoV-2 mRNA vaccine series in solid organ transplant recipients. JAMA 325, 2204–2206 (2021).
doi: 10.1001/jama.2021.7489 pubmed: 33950155 pmcid: 8100911
Rincon-Arevalo, H. et al. Impaired humoral immunity to SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients and dialysis patients. Sci. Immunol. 6, https://doi.org/10.1126/sciimmunol.abj1031 (2021).
Prendecki, M. et al. Humoral and T-cell responses to SARS-CoV-2 vaccination in patients receiving immunosuppression. Ann. Rheum. Dis. 80, 1322–1329 (2021).
doi: 10.1136/annrheumdis-2021-220626 pubmed: 34362747
Styer, L. M. et al. High-throughput multiplex SARS-CoV-2 IgG microsphere immunoassay for dried blood spots: a public health strategy for enhanced serosurvey capacity. Microbiol. Spectr. 9, e0013421 (2021).
doi: 10.1128/Spectrum.00134-21 pubmed: 34319133
Demmer, R. T. et al. Identification of natural SARS-CoV-2 infection in seroprevalence studies among vaccinated populations. Mayo Clin Proc 97, 754–760 (2022).
doi: 10.1016/j.mayocp.2022.02.002 pubmed: 35379422
Martin, C. A. et al. Ethnic differences in cellular and humoral immune responses to SARS-CoV-2 vaccination in UK healthcare workers: a cross-sectional analysis. EClinicalMedicine 58, 101926 (2023).
doi: 10.1016/j.eclinm.2023.101926 pubmed: 37034357 pmcid: 10071048
Magesh, S. et al. Disparities in COVID-19 outcomes by race, ethnicity, and socioeconomic status: a systematic-review and meta-analysis. JAMA Netw. Open 4, e2134147 (2021).
doi: 10.1001/jamanetworkopen.2021.34147 pubmed: 34762110 pmcid: 8586903
Moore, J. T. et al. Disparities in incidence of COVID-19 among underrepresented racial/ethnic groups in counties identified as hotspots during June 5–18, 2020–22 States, February–June 2020. MMWR Morb. Mortal Wkly Rep 69, 1122–1126 (2020).
doi: 10.15585/mmwr.mm6933e1 pubmed: 32817602 pmcid: 7439982
van Buuren, S. & Groothuis-Oudshoorn, K. mice: Multivariate imputation by chained equations in R. J. Stat. Softw. 45, 1–67 (2011).
doi: 10.18637/jss.v045.i03

Auteurs

John S Kim (JS)

Department of Medicine, University of Virginia School of Medicine, Charlottesville, VA, USA.
Department of Medicine, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA.
ORCID: 0000-0002-8887-150X

Yifei Sun (Y)

Department of Biostatistics, Columbia University Mailman School of Public Health, New York, NY, USA.

Pallavi Balte (P)

Department of Medicine, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA.

Mary Cushman (M)

Department of Medicine, Larner College of Medicine at the University of Vermont, Burlington, VT, USA.
Department of Pathology and Laboratory Medicine, Larner College of Medicine at the University of Vermont, Burlington, VT, USA.
ORCID: 0000-0002-7871-6143

Rebekah Boyle (R)

Department of Pathology and Laboratory Medicine, Larner College of Medicine at the University of Vermont, Burlington, VT, USA.

Russell P Tracy (RP)

Department of Pathology and Laboratory Medicine, Larner College of Medicine at the University of Vermont, Burlington, VT, USA.

Linda M Styer (LM)

Division of Infectious Diseases, Wadsworth Center, New York State Department of Health, Albany, NY, USA.

Taison D Bell (TD)

Department of Medicine, University of Virginia School of Medicine, Charlottesville, VA, USA.

Michaela R Anderson (MR)

Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA.

Norrina B Allen (NB)

Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
ORCID: 0000-0002-6993-4384

Pamela J Schreiner (PJ)

Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis, MN, USA.

Russell P Bowler (RP)

Division of Pulmonary, Critical Care and Sleep Medicine, National Jewish Health, Denver, CO, USA.

David A Schwartz (DA)

Department of Medicine, University of Colorado School of Medicine, Aurora, CO, USA.

Joyce S Lee (JS)

Department of Medicine, University of Colorado School of Medicine, Aurora, CO, USA.

Vanessa Xanthakis (V)

Department of Medicine, Boston University Chobanian and Avedisian School of Medicine, Boston, MA, USA.
Framingham Heart Study, Framingham, MA, USA.

Margaret F Doyle (MF)

Department of Pathology and Laboratory Medicine, Larner College of Medicine at the University of Vermont, Burlington, VT, USA.

Elizabeth A Regan (EA)

Division of Rheumatology, National Jewish Health, Denver, CO, USA.

Barry J Make (BJ)

Division of Pulmonary, Critical Care and Sleep Medicine, National Jewish Health, Denver, CO, USA.

Alka M Kanaya (AM)

Division of General Internal Medicine, University of California San Francisco, San Francisco, CA, USA.

Sally E Wenzel (SE)

Department of Medicine, Department of Immunology, and Department of Environmental Medicine and Occupational Health, University of Pittsburgh School of Medicine, School of Public Health, Pittsburgh, PA, USA.
ORCID: 0000-0002-4242-0164

Josef Coresh (J)

Department of Population Health, New York University Grossman School of Medicine, New York University Langone Health, New York, NY, USA.
Department of Medicine, New York University Grossman School of Medicine, New York University Langone Health, New York, NY, USA.
ORCID: 0000-0002-4598-0669

Carmen R Isasi (CR)

Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY, USA.
ORCID: 0000-0003-2700-9593

Laura M Raffield (LM)

Department of Genetics, University of North Carolina, Chapel Hill, NC, USA.
ORCID: 0000-0002-7892-193X

Mitchell S V Elkind (MSV)

Department of Neurology, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA.
Department of Epidemiology, Columbia University Mailman School of Public Health, New York, NY, USA.

Virginia J Howard (VJ)

Department of Epidemiology, School of Public Health, University of Alabama at Birmingham, Birmingham, AL, USA.

Victor E Ortega (VE)

Division of Respiratory Medicine, Mayo Clinic, Scottsdale, AZ, USA.

Prescott Woodruff (P)

Division of Pulmonary and Critical Care Medicine, University of California San Francisco, San Francisco, CA, USA.

Shelley A Cole (SA)

Population Health Program, Texas Biomedical Research Institute, San Antonio, TX, USA.

Joel M Henderson (JM)

Department of Pathology and Laboratory Medicine, Boston University Chobanian & Avedisian School of Medicine and Boston Medical Center, Boston, MA, USA.

Nicholas J Mantis (NJ)

Division of Infectious Diseases, Wadsworth Center, New York State Department of Health, Albany, NY, USA.
Department of Biomedical Sciences, School of Public Health, University at Albany, Albany, NY, USA.
ORCID: 0000-0002-5083-8640

Monica M Parker (MM)

Division of Infectious Diseases, Wadsworth Center, New York State Department of Health, Albany, NY, USA.

Ryan T Demmer (RT)

Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis, MN, USA. demmer.ryan@mayo.edu.
Department of Epidemiology, Columbia University Mailman School of Public Health, New York, NY, USA. demmer.ryan@mayo.edu.
Division of Epidemiology, Department of Quantitative Health Sciences, College of Medicine and Science, Mayo Clinic, Rochester, MN, USA. demmer.ryan@mayo.edu.

Elizabeth C Oelsner (EC)

Department of Medicine, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA. eco7@cumc.columbia.edu.
ORCID: 0000-0002-7481-9671

Classifications MeSH